Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nemvaleukin alfa
- Development stage
- Phase 2
- Lead developer
- Mural Oncology
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Nemvaleukin alfa is a novel, engineered cytokine and recombinant fusion protein designed to selectively bind to the intermediate-affinity interleukin-2 (IL-2) receptor complex. By doing so, it preferentially activates and expands antitumor CD8+ T cells and natural killer (NK) cells while minimizing the expansion of immunosuppressive regulatory T cells (Tregs). This selective activation leverages the antitumor effects of IL-2 signaling while mitigating toxicities associated with high-affinity IL-2 receptor engagement. Nemvaleukin alfa is being developed primarily for use in cancer immunotherapy, including as monotherapy and in combination with pembrolizumab for advanced solid tumors such as melanoma, ovarian cancer, fallopian tube cancer, peritoneal cancer, squamous cell carcinoma, and other solid tumors. The drug was originally developed by Alkermes and is now under development by Mural Oncology.
- Brand names
- nemvaleukin alfa
- Other names
- nemvaleukinnemvaleukin alfa
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on nemvaleukin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nemvaleukin alfa.